Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) EV-to-EBIT : 0.00 (As of Jun. 06, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Parnell Pharmaceuticals Holdings EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Parnell Pharmaceuticals Holdings's Enterprise Value is $0.00 Mil. Parnell Pharmaceuticals Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2018 was $5.26 Mil. Therefore, Parnell Pharmaceuticals Holdings's EV-to-EBIT for today is 0.00.

The historical rank and industry rank for Parnell Pharmaceuticals Holdings's EV-to-EBIT or its related term are showing as below:

PARNF's EV-to-EBIT is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 16.36
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Parnell Pharmaceuticals Holdings's Enterprise Value for the quarter that ended in Dec. 2018 was $32.02 Mil. Parnell Pharmaceuticals Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2018 was $5.26 Mil. Parnell Pharmaceuticals Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2018 was 16.42%.

Parnell Pharmaceuticals Holdings EV-to-EBIT Historical Data

The historical data trend for Parnell Pharmaceuticals Holdings's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Parnell Pharmaceuticals Holdings EV-to-EBIT Chart

Parnell Pharmaceuticals Holdings Annual Data

Trend

Jun12

Jun13

Jun14

Dec15

Dec16

Dec17

Dec18

EV-to-EBIT

Get a 7-Day Free Trial

-11.48

-6.66

-2.13

-3.09

6.85

Parnell Pharmaceuticals Holdings Semi-Annual Data
	Jun12	Jun13	Jun14	Dec15	Dec16	Dec17	Dec18
EV-to-EBIT	Get a 7-Day Free Trial			-11.48	-6.66	-2.13	-3.09	6.85

Competitive Comparison of Parnell Pharmaceuticals Holdings's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Parnell Pharmaceuticals Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Parnell Pharmaceuticals Holdings's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Parnell Pharmaceuticals Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Parnell Pharmaceuticals Holdings's EV-to-EBIT falls into.

Parnell Pharmaceuticals Holdings EV-to-EBIT Calculation

Parnell Pharmaceuticals Holdings's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	0.000	/	5.256
	=	0.00

Parnell Pharmaceuticals Holdings's current Enterprise Value is $0.00 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Parnell Pharmaceuticals Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2018 was $5.26 Mil.

Parnell Pharmaceuticals Holdings (OTCPK:PARNF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Parnell Pharmaceuticals Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2018 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2018 )	=	EBIT	/	Enterprise Value (Q: Dec. 2018 )
	=	5.256	/	32.01832
	=	16.42 %

Parnell Pharmaceuticals Holdings's Enterprise Value for the quarter that ended in Dec. 2018 was $32.02 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Parnell Pharmaceuticals Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2018 was $5.26 Mil.

Parnell Pharmaceuticals Holdings EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Parnell Pharmaceuticals Holdings's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARNF) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

476 Gardeners Road, Unit 4, Century Estate, Alexandria, Sydney, NSW, AUS, 2015

Website

https://www.parnell.com

Parnell Pharmaceuticals Holdings Ltd is an Australia based veterinary pharmaceutical company. It is focused on developing, manufacturing and commercializing animal health solutions. The group manufactures and market products for companion animals and production animals. The firm also has a pipeline of drug products like Zydax, PAR121 and PAR122 and Luminous which covers therapeutic areas in orthopedics, dermatology, and nutraceuticals. The operating segments of the company are Companion animal, Production animal - U.S., Production animal - rest of world and Contract Manufacturing. It operates internationally and generates the majority of the revenue from the Production animal - U.S. segment which covers the group's reproductive hormone portfolio across production animal in the USA.